<DOC>
	<DOCNO>NCT00422617</DOCNO>
	<brief_summary>An open-label , multicentre study evaluate efficacy safety one course weekly intramuscular administration Amevive Taiwan patient chronic plaque psoriasis</brief_summary>
	<brief_title>Evaluate Efficacy Safety One Course Amevive Taiwan Patients</brief_title>
	<detailed_description>The purpose present study establish efficacy safety one course weekly 15 mg intramuscular ( IM ) administration AMEVIVE alternate study population address issue peak time response measure proportion patient achieve â‰¥ 75 % reduction PASI time completion treatment .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Must give write informed consent Must &gt; = 16 year age Must diagnose chronic plaque psoriasis least one year require systemic phototherapy Must CD4+ lymphocyte count lower limit normal Must BSA &gt; = 10 % Current erythrodermic , generalize pustular , guttate psoriasis Serious local infection systemic infection within 3 month prior first dose alefacept History clinical significant disease would contraindicate study determine investigator Prior history systemic malignancy , untreated localised skin canceer &gt; 10 squamous cell carcinoma Current enrollment investigational drug study within 30 day prior study drug administration Treatment systemic immunosuppressant agent within 4 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
</DOC>